TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dimerix Limited ( (AU:DXB) ) has issued an update.
Dimerix Limited reported a significant increase in revenues from ordinary activities, up 914% to $5.9 million for the year ended June 30, 2025. Despite this revenue growth, the company recorded a loss of $13.25 million, which is a 22% improvement from the previous year’s loss. The company did not declare any dividends during this period. This financial performance reflects Dimerix’s ongoing investment in its product development pipeline, which is crucial for its long-term strategic positioning in the biotechnology sector.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.58 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of pharmaceutical products. The company is involved in the research and development of therapies for various medical conditions, with a particular emphasis on kidney disease and other chronic ailments.
Average Trading Volume: 1,603,583
Technical Sentiment Signal: Buy
Current Market Cap: A$282.1M
Learn more about DXB stock on TipRanks’ Stock Analysis page.